Selective CDK9 and CDK4/6 inhibitors with potential application across a range of cancers now available for partnering.
About
A seasoned team experienced in developing cancer medicines to create a fully integrated oncology company.
Selective CDK9 and CDK4/6 inhibitors with potential application across a range of cancers now available for partnering.